Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
39°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Gilead Sciences, Inc.
< Previous
1
2
3
4
5
6
7
8
Next >
Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma
June 28, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks
June 24, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite Joint Venture - Fosun Kite - Gains the First CAR T-cell Therapy Approval in China
June 23, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets
June 21, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021
June 21, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies
June 17, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C
June 10, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation
June 04, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Trodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
June 04, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021
May 19, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Investor Conferences
May 14, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Investor Conferences
May 06, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces Second Quarter 2021 Dividend
April 29, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces First Quarter 2021 Financial Results
April 29, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces Steps to Expand Availability of Remdesivir in India
April 26, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Release First Quarter 2021 Financial Results on Thursday, April 29, 2021
April 15, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer
April 13, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
April 07, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.